The Vasopressin V1bReceptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studies
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: These studies were designed to evaluate the efficacy and tolerability of the first nonpeptide vasopressin V(1b) receptor antagonist, SSR149415, in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). METHOD: Studies were randomized 8-week, double-blind, placebo-controlled trials evaluating 100- and 250-mg twice daily doses of SSR149415, placebo, and escitalopram 10 mg/day or paroxetine 20 mg/day, conducted from August 2006 through February 2008. Participants met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for MDD or GAD. Baseline Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HDRS) total scores were ≥ 24 and 18, respectively, and in the GAD trial baseline Hamilton Anxiety Rating Scale (HARS) score was ≥ 22. Primary efficacy variables included changes from baseline in total score on HDRS or HARS and MADRS, and the secondary variable included changes in the Clinical Global Impressions-Severity of Illness score (CGI-S). A 4-week, double-blind, placebo-controlled study evaluating the effect of 100- and 250-mg twice daily doses of SSR149415 on the hypothalamic-pituitary-adrenal (HPA) axis in MDD patients was also conducted. RESULTS: In the GAD trial, SSR149415 did not separate from placebo on the primary (HARS-100 mg: P = .29; 250 mg: P = .21) and secondary (CGI-S-100 mg: P = .18; 250 mg: P = .24) outcome measures, while paroxetine demonstrated efficacy (HARS: P = .003; CGI-S: P = .01). In 2 MDD trials, SSR149415-treated patients did not show significant improvement from baseline on any outcome measure compared with placebo-treated patients (HDRS-100 mg: P = .21 and .48, respectively; 250 mg: P = .22 and P = .46, respectively; CGI-S-100 mg: P = .64 and P = .82, respectively; 250 mg: P = .33 and P = .08, respectively). In the third MDD study, SSR149415 250 mg (P = .04), but not escitalopram (P = .15), demonstrated significant improvement compared to placebo on the HDRS total score at week 8. SSR149415 had no deleterious effects on the HPA axis. CONCLUSIONS: These studies demonstrate that SSR149415 may not be useful for the treatment of GAD and that its antidepressant potential needs to be further evaluated. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00374166 (Sanofi ID number: DFI5880), NCT00361491 (Sanofi ID number: DFI5879), NCT00358631 (Sanofi ID number: DFI5878), NCT01606384 (Sanofi ID number: PDY5467).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another trial with 100 mg and 250 mg SSR149415 did not show a significant improvement compared to placebo.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [86]
In the citing paper
“however, the trial failed because the comparator escitalopram did not achieve a significant reduction in the HDRS.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [86]
In the citing paper
“Interestingly, SSR149415 with dosage up to 250 mg did not reduce the cortisol response to the CRH challenge, while doses higher than 250 mg significantly reduced the cortisol response.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [86]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
A stagewise rejective multiple test procedure based on a modified Bonferroni test
HOMMEL, G. (1988) · Biometrika · doi:10.1093/biomet/75.2.383 · Cited by 1,367
A Unified Approach to Mixed Linear Models
McLean, R. A., Sanders, W. L., & Stroup, W. W. (1991) · The American Statistician · doi:10.1080/00031305.1991.10475767 · Cited by 601
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471
Self-citationPurba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“SSR149415 V1b antagonist (202) None MDD + GAD (202) None”
BackgroundJakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Role of neuropeptides in anxiety, stress, and depression: From animals to humans
Kormos, V., & Gaszner, B. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.014 · Cited by 329
“More recently Griebel et al. (2012) summarized the results of four clinical trials with SSR149415 and concluded that the V1b receptor antagonist did not have a significant effect on generalized anxiety disorder and in two of three trials on depressed subjects SSR149415 failed to improve the mood…”
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
“Also worth mention here is a very recent human trial of the vasopressin V1b receptor antagonist SSR149415, which showed negligible anxiolytic effects, and antidepressant effects that warrant further study (Griebel et al., 2012).”
BackgroundRutigliano, G., Rocchetti, M., Paloyelis, Y., Gilleen, J., Sardella, A., Cappucciati, M., Palombini, E., Dell’Osso, L., Caverzasi, E., Politi, P., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.117 · Cited by 149
“…there is also growing interest in the potential for synthetic neuropeptides in treatment of psychosis (for a comprehensive review see (Gumley et al., 2014)), autism spectrum disorders (ASD) (Thompson et al., 2006; Uzunova et al., 2015), and affective and anxiety disorders (Griebel et al., 2012).”
BackgroundMethodThe neurobiological correlates of childhood adversity and implications for treatment
Tyrka, A. R., Burgers, D. E., Philip, N. S., Price, L. H., & Carpenter, L. L. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12143 · Cited by 142
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“Clinical trials have been conducted with 3 different V 1B receptor antagonists for the treatment of MDD: the compound with the largest clinical database Sanofi's SSR149415/nelivaptan [86], AbbVie’s ABT-436 [87], and Taisho Pharmaceutical’s TS-121 [88].”
MethodBelzung, C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.342 · Cited by 106
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
“Unfortunately, trials suggest that the clinical antidepressant effects of SSR149415 are still limited (Griebel et al., 2012).”
BackgroundKokras, N., Hodes, G. E., Bangasser, D. A., & Dalla, C. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14710 · Cited by 100
Experimental medication treatment approaches for depression
Ionescu, D., & Papakostas, G. I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.33 · Cited by 83
“64 reported data from three randomized, double-blind, 8-week trials of SSR149415 for MDD.”
Tanti, A., & Belzung, C. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1612-z · Cited by 85
“…fact not antidepressant drugs, as despite a number of preclinical studies suggesting an antidepressant-like profile of these compounds, little clinical evidence has been found in Phase II trials with, for example, CRH1 antagonists or V1b antagonists (Griebel et al. 2012; Griebel and Holsboer 2012).”
BackgroundIijima, M., Yoshimizu, T., Shimazaki, T., Tokugawa, K., Fukumoto, K., Kurosu, S., Kuwada, T., Sekiguchi, Y., & Chaki, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12699 · Cited by 55
“Recent clinical studies have indicated that SSR149415 failed to satisfy the efficacy requirements in patients with MDD and generalized anxiety disorder (Griebel et al., 2012).”
BackgroundThe Role of Serotonin, Vasopressin, and Serotonin/Vasopressin Interactions in Aggressive Behavior
Morrison, T. R., & Melloni, R. H. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_283 · Cited by 57
“…V1A receptor influences maternal care, mate-bonding, and social recognition (Bielsky et al. 2004; Pitkow et al. 2001; Wersinger et al. 2002) while the V1B receptor is associated with depression, the stress response, and anxiety (Griebel et al. 2012, 2003; Salomé et al. 2006; Stemmelin et al. 2005).”
BackgroundLee, R. J., Coccaro, E. F., Cremers, H., McCarron, R., Lu, S.-F., Brownstein, M. J., & Simon, N. G. (2013) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2013.00100 · Cited by 50
“Small-molecule V1b receptor antagonists have thus far not proven effective for the treatment of depression (Griebel et al., 2012), which may be due to the relatively low expression and restricted, hypothalamic distribution of the receptor.”
BackgroundWitkin, J. M., LIPPA, A. S., Smith, J. L., Jin, X., Ping, X., Biggerstaff, A., Kivell, B. M., Knutson, D. E., Sharmin, D., Pandey, K. P., et al. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173321 · Cited by 51
Are neuropeptides relevant for the mechanism of action of SSRIs?
Gołyszny, M., & Obuchowicz, E. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.02.002 · Cited by 47
Gołyszny, M. J., Obuchowicz, E., & Zielinski, M. W. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102216 · Cited by 44
Social Context, Stress, Neuropsychiatric Disorders, and the Vasopressin 1b Receptor
Caldwell, H. K., Aulino, E. A., Rodriguez, K. M., Witchey, S. K., & Yaw, A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00567 · Cited by 40
“In a Phase II clinical trial in patients with major depressive disorder or generalized anxiety disorder, the effects of treatment with SSR149415 did not differ from the effects of the placebo (Roper et al., 2011; Griebel et al., 2012).”
BackgroundCid-Jofré, V., Moreno, M., Reyes-Parada, M. I., & Renard, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112077 · Cited by 43
“However, doubled-blind placebo-controlled clinical trials (Clinicaltrials.gov identifiers: NCT00374166, NCT00361491, NCT00358631, and NCT01606384) showed that SSR149415 failed to demonstrate competence in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) [202], leading to disconti…”
BackgroundMethodInfluentialFodor, A., Kovács, K., Balázsfi, D., Klausz, B., Pintér, O., Demeter, K., Daviu, N., Rabasa, C., Rotllant, D., Nadal, R. A., et al. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.041 · Cited by 40
Vasopressin V1B receptor antagonists as potential antidepressants
Chaki, S. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab013 · Cited by 34
Ding, Y., Wei, Z., Yan, H., & Guo, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732157 · Cited by 34
“Additional well-designed RCTs with prolonged follow-up periods investigating HPA-modulating treatments in different depression subtypes are needed.”
BackgroundInfluentialVasopressin and alcohol: a multifaceted relationship
Harper, K. M., Knapp, D. J., Criswell, H. E., & Breese, G. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5099-x · Cited by 38
“Two of the clinical trials in depressed patients showed no improvement on the Hamilton Depression Rating Scale or the Clinical Global Impressions-Severity of Illness score, although a third trial in depressed patients showed improvement on the Hamilton Depression Rating Scale without effects on the Montgomery–Asberg D…”
InfluentialBaumeister, D., Lightman, S. L., & Pariante, C. M. (2016) · Psychopathology Review · doi:10.5127/pr.034413 · Cited by 36
Advances in novel molecular targets for antidepressants
Wang, Q., & Dwivedi, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110041 · Cited by 34
“These include forced swim test (Griebel et al., 2012; Overstreet and Griebel, 2005), the olfactory bulbectomy (Iijima and Chaki, 2007) and unpredictable chronic mild stress (Alonso et al., 2004; Griebel et al., 2002a).”
BackgroundThe New Molecular Landscape of Cushing's Disease
Sbiera, S., Deutschbein, T., Weigand, I., Reincke, M., Faßnacht, M., & Allolio, B. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.08.003 · Cited by 32
Kamiya, M., Sabia, H. D., Marella, J., Fava, M., Nemeroff, C. B., Umeuchi, H., Iijima, M., Chaki, S., & Nishino, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.017 · Cited by 28
Copeptin during rest and exercise in major depression
Krogh, J., Goetze, J. P., Jørgensen, M. B., Kristensen, L. Ø., Kistorp, C., & Nordentoft, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.007 · Cited by 29
“In favor of the current results is a recent publication found that found no antidepressant effect of a V1b receptor antagonist compared to placebo in two of three trials (Griebel et al., 2012).”
ResultJacobsen, J. P. R., Plenge, P., Sachs, B. D., Pehrson, A. L., Cajina, M., Du, Y., Roberts, W. L., Rudder, M. L., Dalvi, P. H., Robinson, T. J., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3595-1 · Cited by 29
“Regrettably, once promising compounds, such as neuropeptide antagonists (Binneman et al. 2008; Griebel et al. 2012; Keller et al. 2006; Manning et al. 2012; Neurocrine 2013) and selective noradrenaline reuptake inhibitors (Eyding et al. 2010; Michelson et al. 2007; Preti 2002), appear to have…”
BackgroundNeuroendocrine Regulation of Anxiety: Beyond the Hypothalamic‐Pituitary‐Adrenal Axis
Borrow, A. P., Stranahan, A. M., Suchecki, D., & Yunes, R. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12403 · Cited by 35
New agents and perspectives in the pharmacological treatment of major depressive disorder
Sanches, M., Quevedo, J., & Soares, J. C. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110157 · Cited by 31
“Furthermore, the antidepressant efficacy of SSR149415, a vasopressin 1b receptor antagonist, has been evaluated in three clinical trials, with mixed results (Griebel et al., 2012).”
BackgroundPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C. R., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19203 · Cited by 31
Kanes, S., Dennie, L., & Perera, P. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s402831 · Cited by 31
“The V1b receptor antagonist SSR149415 failed to clearly demonstrate effective treatment of symptoms in patients with generalized anxiety disorder or MDD, although doses used in these trials may have been insufficient to block HPA axis activity and achieve therapeutic effects; these failures may also reflect the hetero…”
Katz, D. A., Liu, W., Locke, C. S., Dutta, S., & Tracy, K. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4089-5 · Cited by 24
“ABT-436’s effects on the HPA axis might not be as robust under less controlled conditions, with longer dosing duration or particularly in patient populations such as MDD or GAD in which there is more variability of HPA axis function.”
BackgroundInfluentialPirrone, F., Pierantoni, L., Bossetti, A., Uccheddu, S., & Albertini, M. (2019) · Animals · doi:10.3390/ani9121033 · Cited by 23
“being useful for the treatment of generalized anxiety disorder [56].”
BackgroundBalázsfi, D., Pintér, O., Klausz, B., Kovács, K., Fodor, A., Török, B., Engelmann, M., & Zelena, D. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.09.011 · Cited by 23
“However, a clinical study using SSR 149415 was unable to proof an effect on anxiety; and there was only a mild, not always reproducible, effect on depressive symptoms (Griebel et al., 2012).”
ResultVasopressinergic control of stress-related behavior: studies in Brattleboro rats
Csikota, P., Fodor, A., Balázsfi, D., Pintér, O., Mizukami, H., Weger, S., Heilbronn, R., Engelmann, M., & Zelena, D. (2016) · Stress · doi:10.1080/10253890.2016.1183117 · Cited by 21
“, 2002) as well as in major depression compared to generalized anxiety disorder in patients (Griebel et al., 2012).”
BackgroundResultInfluentialHarper, K. M., Knapp, D. J., Butler, R. K., Cook, C. A., Criswell, H. E., Stuber, G. D., & Breese, G. R. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14163 · Cited by 25
“There are past and ongoing clinical trials to determine the efficacy of vasopressin receptor antagonism on individuals suffering from anxiety (Harper et al., 2018a, Griebel et al., 2012).”
BackgroundTranslating depression biomarkers for improved targeted therapies
Bredt, D. S., Furey, M. L., Chen, G., Lovenberg, T., Drevets, W. C., & Manji, H. K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.013 · Cited by 23
New dimensions in the use of rodent behavioral tests for novel drug discovery and development
Hoffman, K. L. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1153624 · Cited by 20
Hu, H., Zarate, C. A., & Verbalis, J. G. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13703 · Cited by 20
“122 TS-121 (now known as ANC-501), which was examined for use in individuals with MDD, similarly resulted in no statistically signi fi cant improvement in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS); however, the sample size was small, and the authors…”
Agorastos, A., Sommer, A., Heinig, A., Wiedemann, K., & Demiralay, C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00453 · Cited by 20
Chaki, S., Shimazaki, T., Nishiguchi, M., Funakoshi, T., Iijima, M., Ito, A., Kanuma, K., & Sekiguchi, Y. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.05.018 · Cited by 19
Chapter 4. Psychoneuroendocrinology
Sforzini, L., Weston, F. I., & Pariante, C. M. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as04 · Cited by 16
Finger release sequence for fastball and curveball pitches.
Stevenson, J. M. (1985) · PubMed · Cited by 22
Vasopressin and post-traumatic stress disorder
Sipos, E., Török, B., Barna, I., Engelmann, M., & Zelena, D. (2020) · Stress · doi:10.1080/10253890.2020.1826430 · Cited by 16
V1bvasopressin receptor trafficking and signaling: Role of arrestins, G proteins and Src kinase
Perkovska, S., Méjean, C., Ayoub, M. A., Li, J., Hemery, F., Corbani, M., Laguette, N., Ventura, M. A., Orcel, H., Durroux, T., et al. (2017) · Traffic · doi:10.1111/tra.12535 · Cited by 15
Vasopressin as Possible Treatment Option in Autism Spectrum Disorder
László, K., Vörös, D., Correia, P., Fazekas, C. L., Török, B., Plangár, I., & Zelena, D. (2023) · Biomedicines · doi:10.3390/biomedicines11102603 · Cited by 13
“Despite mixed results, a recent meta-analysis found moderate evidence that a 6-week OT treatment might improve the reduced interest and repetitive behavior of ASD children and the effect lasted for at least 6 months [374].”
BackgroundResultAdvances in Psychopharmacology for Anxiety Disorders
Garakani, A., Murrough, J. W., & Iosifescu, D. V. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.152 · Cited by 14
ANXIOLYTICS: Origins, drug discovery, and mechanisms
Witkin, J. M., & Barrett, J. E. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173858 · Cited by 15
Miklos, Z., Flynn, F. W., & Lessard, A. (2014) · Brain Research · doi:10.1016/j.brainres.2014.09.043 · Cited by 10
Evidence for the contribution of vasopressin V1B receptors in the pathophysiology of depression
Guan, W., Wang, Q., & Sheng, X.-M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116672 · Cited by 10
The Role of Vasopressin in Anxiety and Depression
Morales‐Medina, J. C., Witchey, S. K., & Caldwell, H. K. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_40 · Cited by 13
High-Contrast PET Imaging of Vasopressin V1B Receptors with a Novel Radioligand, 11C-TASP699
Koga, K., Nagai, Y., Hanyu, M., Yoshinaga, M., Chaki, S., Ohtake, N., Ozaki, S., Zhang, M., Suhara, T., & Higuchi, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188698 · Cited by 9
Advocating for Mutually Beneficial Access to Shelved Compounds
Pulley, J. M., Jerome, R. N., Shirey-Rice, J. K., Zaleski, N. M., Naylor, H. M., Pruijssers, A. J. P., Jackson, J. C., Bernard, G. R., & Holroyd, K. J. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0090 · Cited by 9
Holsboer, F., & Ising, M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2372-3549 · Cited by 9
Török, B., Fodor, A., Zsebők, S., Sipos, E., & Zelena, D. (2021) · Brain Sciences · doi:10.3390/brainsci11040444 · Cited by 9
“showed that the nonpeptide V1bR antagonist SSR149415 may not be useful for the treatment of generalized anxiety disorder in adult patients [11].”
BackgroundJavelot, H. (2015) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2015.09.001 · Cited by 9
Yun, S. H., Xia, L., Kim, S. H., & Lee, Y. R. (2016) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201600226 · Cited by 8
Inatani, S., Mizuno‐Yasuhira, A., Kamiya, M., Nishino, I., Sabia, H. D., & Endo, H. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2273 · Cited by 7
Hormone circuit explains why most HPA drugs fail for mood disorders and predicts the few that work
Milo, T., Halber, S. N., Raz, M., Danan, D., Mayo, A., & Alon, U. S. (2025) · Molecular Systems Biology · doi:10.1038/s44320-024-00083-0 · Cited by 8
“Accordingly, V1bR antagonists did not show statistically signi fi cant ef fi cacy in clinical trials for major depressive disorder and generalized anxiety disorder (Griebel et al, 2012; Chaki, 2021; Kamiya et al, 2020).”
Epigenetic Modulation of Vasopressin Expression in Health and Disease
Török, B., Fazekas, C. L., Szabó, A., & Zelena, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179415 · Cited by 7
“This could be one r as n why this compound failed in clinical trials [30].”
BackgroundNovel, potent, selective and brain penetrant vasopressin 1b receptor antagonists
Geneste, H., Bhowmik, S., van Gaalen, M. M., Hornberger, W., Hutchins, C. W., Netz, A., Oost, T. K., & Unger, L. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.043 · Cited by 6
Vasopressin V1a and V1b receptor modulators: a patent review (2012 – 2014)
Ślusarz, M. J. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1026257 · Cited by 7
Borrow, A. P., Stover, S. A., Bales, N. J., & Handa, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00010-9 · Cited by 5
Frycz, B. A., Dutsch-Wicherek, M., Płaza, O., Szulc, A., Bijata, M., Włodarczyk, J., & Dzwonek, J. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00827-9 · Cited by 2
Gupta, J. K., Singh, K., Bhatt, A., Porwal, P., Rani, R., Dubey, A., Jain, D., & Nand, S. (2024) · 3 Biotech · doi:10.1007/s13205-024-04104-5 · Cited by 5
TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor
Koga, K., Yoshinaga, M., Uematsu, Y., Nagai, Y., Miyakoshi, N., Shimoda, Y., Fujinaga, M., Minamimoto, T., Zhang, M.-R., Higuchi, M., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232942 · Cited by 3
“This utility would be of particular significance in a receptor occupancy study, which would help to determine the optimal doses of V1B receptor antagonists for clinical trials (Griebel et al., 2012; Katz et al., 2016).”
BackgroundA cross talk on the role of contemporary biomarkers in depression
Vyas, A., & Doshi, G. (2024) · Biomarkers · doi:10.1080/1354750x.2024.2308834 · Cited by 2
“On the other hand, the v1b receptor antagonist SSR149415 failed to demonstrate effective treatment of symptoms in patients with generalized anxiety disorder or MDD; these failures may also reflect the illness’s heterogeneity or the large patient populations enrolled (Griebel et al. 2012).”
BackgroundŚlusarz, M. J. (2024) · Biopolymers · doi:10.1002/bip.23627 · Cited by 2
“Nelivaptan has undergone clinical trials which, unfortunately, demonstrated that it may not be useful for the treatment of MDD [31].”
Arginine vasopressin: A promising therapeutic target for metabolic syndrome
Elsamad, G., Alotaibi, M. I., Echtay, K. S., Murphy, D., & Greenwood, M. P. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104936 · Cited by 1
Developments in Psychopharmacology for Major Depressive Disorder
Chang, T. E., & Stahl, S. M. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.452 · Cited by 1
Self-citationNovel and Investigational Drugs in Depression
Shapiro, D. N., & Stahl, S. M. (2014) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2014/11590 · Cited by 1
“Its potential as an antidepressant calls for further evaluation [113].”
BackgroundSelf-citationOxytocin and obsessive–compulsive disorder
Soltan, M. (2022) · Egyptian Journal of Psychiatry · doi:10.4103/ejpsy.ejpsy_28_21 · Cited by 1
González, C. Á., Zaragozá, C., & Lopez-Munoz, F. J. (2020) · Revista de Investigación y Educación en Ciencias de la Salud (RIECS) · doi:10.37536/riecs.2020.5.2.214 · Cited by 5
Pharmacological Treatment of Generalized Anxiety Disorder (GAD)
Baldwin, D. S. (2020) · Wiley eBooks · doi:10.1002/9781119189909.ch14 · Cited by 1
THOMSON, F. J., & Napier, S. E. (2014) · Springer eBooks · doi:10.1007/978-3-642-27772-6_386-2
Mucke, H. A. (2014) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.14.1
THOMSON, F. J., & Napier, S. J. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_386
zu Eulenburg, C., Gehrlach, D., Myhsok, M., Strote, C., Arvastson, L., Müller‐Myhsok, B., Griebel, G., & Eriksson, H. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1645225
“Nelivaptan is a potent and selective vasopressin V1b receptor antagonist that was studied in a total of 19 clinical trials in Phase 1 and Phase 2 as a potential treatment for MDD and generalized anxiety disorder (GAD) (11).”
Self-citationBindingDB (2020) · UC San Diego · doi:10.7270/q2cc13cc
Metadata
- Authors
- Griebel, G., Beeské, S., & Stahl, S. M.
- Affiliations
- Sanofi (France) (FR)
- Corresponding author
- Griebel, Guy
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2012-10-16
- Volume
- 73
- Issue
- 11
- Pages
- 1403-1411
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2061265867
- Cited by
- 81
- References
- 22
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 8 · 2023: 3 · 2022: 2 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 10 · 2013: 7 · 2012: 1
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- major depressive disorder, generalized anxiety disorder, antidepressant efficacy, tolerability, paroxetine, escitalopram, hypothalamic-pituitary-adrenal axis, placebo comparison, dose comparison
- MeSH terms
- Adolescent, Adult, Antidepressive Agents, Anxiety Disorders, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Humans, Indoles, Male, Middle Aged, Pyrrolidines, Recurrence, Anti-Anxiety Agents, Citalopram, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase II as Topic, Paroxetine, Young Adult, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.